Core Viewpoint - Zhongbei Communication has received approval from the Shanghai Stock Exchange for its application to issue shares to specific investors, pending final registration approval from the China Securities Regulatory Commission (CSRC) [1][3] Fundraising Details - The total amount to be raised through the issuance is not to exceed 1,920.2348 million yuan, with net proceeds intended for investment in the Intelligent Computing Center project, 5G communication network construction, and repayment of bank loans [1][2] - The planned investment amounts for the projects are as follows: Intelligent Computing Center project 1,304.5039 million yuan, 5G communication network project 532.0385 million yuan, and repayment of bank loans 300 million yuan [2] Issuance Structure - The issuance will target no more than 35 specific investors, including qualified institutional investors such as securities investment fund management companies, securities companies, trust investment companies, financial companies, insurance institutions, and qualified foreign institutional investors [2] - The final number of shares to be issued will be determined based on the total amount raised divided by the issuance price, not exceeding 30% of the company's total share capital prior to the issuance [3] Shareholder Information - As of March 31, 2025, the controlling shareholders are Li Liubing and Mei Man, holding a combined 26.77% of the company's total shares [4] - Following the issuance, if the maximum number of shares is issued, the total share capital will increase from 434,244,123 shares to 564,517,359 shares, with the combined ownership percentage of Li Liubing and Mei Man decreasing to 20.59%, indicating no change in control [4] Underwriting and Compliance - The underwriting institution for this issuance is Guotai Junan Securities Co., Ltd., with representatives Jiang Zhiqiang and Li Qin overseeing the process [4]

Group 1 - The core point of the news is the performance and financial details of Beijing Saiwei Electronics Co., Ltd., which saw a stock price increase of 5.19% to 26.53 CNY per share, with a trading volume of 1.143 billion CNY and a turnover rate of 7.50%, resulting in a total market capitalization of 19.426 billion CNY [1] - The company specializes in MEMS process development and wafer manufacturing, as well as GaN epitaxial material growth and chip design, with its main business revenue composition being 54.30% from MEMS wafer manufacturing, 39.14% from MEMS process development, 4.90% from other sources, and 1.67% from semiconductor equipment [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Haitong Asset Management has a significant position in Saiwei Electronics, with the Guotai Junan CSI 1000 Preferred Stock A Fund (019505) holding 229,300 shares, accounting for 0.89% of the fund's net value, ranking as the tenth largest holding [2] - The fund has achieved a year-to-date return of 39.37%, ranking 1063 out of 4222 in its category, and a one-year return of 92.71%, ranking 732 out of 3804 [2]

格隆汇9月18日｜据21财经，国泰海通董事长朱健将担任中国资本市场学会期货与衍生品专委会主任委 员，南华期货董事⻓罗旭峰、汇添富基⾦名誉董事⻓李文将担任副主任委员。据悉，期货与衍⽣品专业 委员会的主要职责为重点围绕聚焦国家重⼤战略完善期货市场品种布局，提升⼤宗商品价格影响⼒和⾦ 融资产定价能⼒；促进⾦融机构衍⽣品业务规范发展，深化资本市场领域衍⽣品监管改⾰等开展研究。 ...

智通财经APP获悉，国泰海通发布研报称，维持同程旅行(00780)增持评级。考虑OTA行业竞争格局依然 稳定，且公司通过补贴效率提升等方式维持利润率稳步提升，维持公司25/26/27年经调整归母净利润至 33.11/38.47/44.02亿元人民币(下同)。考虑公司自身成长性和业绩弹性，和相比携程体量，给予2025年 18xPE估值，维持目标市值596亿元人民币，以1HKD=0.9128CNY汇率计算，对应653亿港币，对应目标 价27.88元港币。 国泰海通主要观点如下： 25Q2业绩超预期，酒旅需求维持景气并驱动GMV同比恢复正增长;行业竞争格局稳定，通过营销补贴效 率提升驱动核心OTA利润率继续稳步提升。 业绩简述 25Q2公司实现收入46.69亿元，同比+10%，核心OTA实现收入40.08亿元，同比+13.66%。经调整净利润 7.75亿元/yoy+18%，经调整净利率16.6%/yoy+1.1pct。其中，核心OTA平台营业利润10.70亿/+24.69%， 核心OTA营业利润率26.7%/+2.4pct。业绩超预期，酒旅高景气且GMV增速回正。①本季财报重点关注 1)交通票务增速放缓对收入的拖累 ...

Core Viewpoint - The report from Guotai Junan maintains an "overweight" rating for Tongcheng Travel (00780), citing a stable competitive landscape in the OTA industry and the company's ability to enhance profit margins through improved subsidy efficiency [1] Financial Performance - In Q2 2025, the company achieved revenue of 4.669 billion yuan, a year-on-year increase of 10%, with core OTA revenue reaching 4.008 billion yuan, up 13.66% [3] - Adjusted net profit for Q2 2025 was 777.5 million yuan, reflecting an 18% year-on-year growth, with an adjusted net profit margin of 16.6%, up 1.1 percentage points [3][4] - Core OTA operating profit was 1.07 billion yuan, a 24.69% increase, with an operating profit margin of 26.7%, up 2.4 percentage points [3] Market Dynamics - The competitive landscape remains stable, with no significant intensification of competition, as evidenced by a 2.2 percentage point decrease in sales expense ratio [4] - The improvement in marketing efficiency continues to drive profit growth, indicating strong certainty in profit growth despite the competitive environment [4] Growth Outlook - The company maintains adjusted net profit forecasts for 2025, 2026, and 2027 at 3.311 billion, 3.847 billion, and 4.402 billion yuan respectively [1] - The target market capitalization is set at 59.6 billion yuan, translating to a target price of 27.88 HKD based on an 18x PE valuation for 2025 [1]

智通财经APP获悉，国泰海通发布研报称，维持BOSS直聘-W(02076)增持评级。受宏观经济波动及自身 增速均值回归的影响，公司收入增速放缓，但公司进行了出色的费用控制，在保证核心经营指标继续正 增长的情况下，利润率继续提升。考虑宏观经济波动，维持2025/26/27年经调整归母净利润至 32.75/39.64/46.7亿元人民币(下同)。给予2025年高于行业平均30xPE估值，2025年目标市值950亿元人民 币，以1HKD=0.9109CNY汇率计算，对应1,043亿港币，对应目标价109.66元港币。 国泰海通主要观点如下： 25Q2业绩超预期，尽管收入增速放缓，但受益于规模经济，费用率方面提效明显。后续预期相对乐 观，收入增速有望逐季改善。业绩简述：公司25Q2营业收入21.02亿/+9.7%;GAAP净利润7.11亿/+70.4%; 经调整净利润9.41亿/+30.9%。股息及分红：宣布8,000万美元股息+2.5亿美元回购计划。 业绩超预期，收入放缓但利润持续释放 收入增速预计环比改善，AI布局及落地规划加速 ①根据公司业绩指引，预计25Q3收入为21.3~21.6亿元，同比+11.4~13% ...

Core Viewpoint - The report maintains a buy rating for BOSS Zhipin-W (02076), highlighting a slowdown in revenue growth due to macroeconomic fluctuations and mean reversion, but effective cost control has led to continued profit margin improvement [1] Group 1: Financial Performance - In Q2 2025, the company reported revenue of 2.102 billion RMB, a year-on-year increase of 9.7%, and a GAAP net profit of 711 million RMB, up 70.4% [2] - Adjusted net profit for Q2 2025 was 941 million RMB, reflecting a 30.9% increase [2] - The company announced a dividend of 80 million USD and a share repurchase plan of 250 million USD [2] Group 2: Profitability and Cost Management - The company experienced a significant improvement in cost efficiency, with sales expense ratio down by 8.47 percentage points and R&D expense ratio down by 3.36 percentage points [3] - The reduction in stock-based compensation (SBC) contributed to a lower SBC expense ratio of 10.93%, down by 4.80 percentage points [3] - BOSS Zhipin has consistently demonstrated strong performance in profit margins due to low customer acquisition costs and high efficiency in marketing investments [3] Group 3: Future Outlook - Revenue for Q3 2025 is expected to be between 2.13 billion and 2.16 billion RMB, representing a year-on-year increase of 11.4% to 13% [4] - The company has a clear and rational plan for the commercialization of AI in the human resources service sector, with product testing expected to contribute to revenue in the near future [4] - The company is positioned to benefit from improving recruitment demand and cash collection trends, with AI developments anticipated to act as a significant catalyst for revenue growth [4]

Core Viewpoint - Cathay Securities maintains an "Accumulate" rating for Weigao Group (01066), adjusting the EPS forecast for 2025-2027 to 0.44/0.50/0.56 yuan from the previous 0.51/0.57/0.63 yuan, with a target price of 8.00 yuan (equivalent to 8.76 HKD) based on a target PE of 16X for 2026 [1] Group 1: Financial Performance - In H1 2025, the company achieved sales revenue of 6.64 billion yuan, remaining flat year-on-year; adjusted net profit attributable to shareholders was 1.02 billion yuan, a decrease of 6.1% year-on-year, primarily due to price reductions of certain products and increased marketing expenses for new products [2] Group 2: Revenue Segmentation - The general medical device segment generated revenue of 3.30 billion yuan in H1 2025, remaining stable year-on-year, with key products like infusion sets and syringes maintaining stable prices and slight volume growth [3] - The pharmaceutical packaging segment reported revenue of 1.17 billion yuan, also flat year-on-year, with stable domestic sales prices for pre-filled syringes and significant volume growth of approximately 200% for automatic injection pens in the Chinese market [3] - The orthopedic segment's revenue was 730 million yuan, a slight decline of 1.6% year-on-year, but segment profit increased by 74% year-on-year, with spinal products showing double-digit growth [3] - The interventional segment's revenue was 990 million yuan, down 2% year-on-year, while the blood technology segment saw revenue of 450 million yuan, an increase of 8.1% year-on-year, driven by good overseas recovery of the Radiosonde irradiator [3] Group 3: Shareholder Returns - The company has maintained a cash dividend ratio of 30% prior to 2023, increasing to 40% for the full year of 2023, with plans to further raise the dividend ratio to 50% by the end of 2024; the mid-year dividend for 2025 is also planned to remain at 50%, reflecting a strong commitment to shareholder returns [4]

Core Viewpoint - Cathay Securities maintains a "Buy" rating for Weigao Group (01066), adjusting the EPS forecast for 2025-2027 to 0.44/0.50/0.56 yuan from the previous 0.51/0.57/0.63 yuan, with a target price of 8.00 yuan (equivalent to 8.76 HKD) based on a target PE of 16X for 2026 [1] Group 1: Financial Performance - In H1 2025, the company achieved a sales revenue of 6.64 billion yuan, remaining flat year-on-year; adjusted net profit attributable to shareholders was 1.02 billion yuan, a decrease of 6.1% year-on-year, primarily due to price reductions on some products and increased marketing expenses for new products [2] Group 2: Business Segments Performance - The general medical device segment generated revenue of 3.30 billion yuan in H1 2025, remaining stable year-on-year, with key products like infusion sets and syringes maintaining stable prices and slight volume growth [3] - The pharmaceutical packaging segment reported revenue of 1.17 billion yuan, also flat year-on-year, with stable domestic sales prices for pre-filled syringes and significant volume growth of approximately 200% for automatic injection pens [3] - The orthopedic segment's revenue was 730 million yuan, a slight decline of 1.6% year-on-year, but segment profit increased by 74% year-on-year, with double-digit growth in spinal products [3] - The interventional segment's revenue was 990 million yuan, down 2% year-on-year, while the blood technology segment saw revenue of 450 million yuan, an increase of 8.1% year-on-year, with good recovery in overseas sales of the Radiosurgery device [3] Group 3: Shareholder Returns - The company has maintained a cash dividend ratio of 30% prior to 2023, increasing to 40% for the full year of 2023, and plans to further raise the dividend ratio to 50% by the end of 2024, with a proposed 50% dividend ratio for the mid-2025 period, highlighting a strong commitment to shareholder returns [4]

美联储如期降息 25 基点，承认劳动力市场走弱，提及通胀上行；点阵图显示年内预计还降息两次，明年 预计降息一次；鲍威尔称本次会议 50 基点降息呼声不高。美联储给出的信号鹰鸽参半，主要资产震荡。（华 尔街见闻） 铅趋势强度：0 注：趋势强度取值范围为【-2,2】区间整数。强弱程度分类如下：弱、偏弱、中性、偏强、强，-2 表示 最看空，2 表示最看多。 2025 年 09 月 18 日 铅：库存减少，支撑价格震荡 季先飞 投资咨询从业资格号：Z0012691 jixianfei@gtht.com 【基本面跟踪】 | | 昨日值 | 较前日变动/涨跌幅 | | 昨日值 | 较前日变动/涨跌幅 | | --- | --- | --- | --- | --- | --- | | 沪铅主力收盘价 | 17100 | 0.26% | 伦铅 3M 电子盘收 | 2006.5 | 0.25% | | （元/吨） | | | 盘（美元/吨） | | | | 沪铅主力成交量 | 44958 | -10020 | 伦铅成交量（手） | 4966 | -550 | | （手） | | | | | | | 沪铅主力持仓量 | 4219 ...